Talphera Q4 2023 Earnings Call Transcript

Quartr
Provided by Quartr
March 6, 2024

There are 5 speakers on the call.

Operator

Welcome to the Talferra 4th Quarter 2023 Financial Results Conference Call. This call is being webcasted live via the Events page of the Investors section of Talfaira's website at www.talferra.com. This call is the property of Talferra and any recording, reproduction or transmission of this call without the expressed written consent of Talferra is strictly prohibited. As a reminder, this webcast is being recorded. You may listen to a replay of this webcast by going to the Investors section of Talferra's website.

Operator

I would now like to turn the call over to Raffi Esadorian, Talferra Pharmaceuticals' Chief Financial Officer. Please go ahead.

Speaker 1

Thank you for joining us on the call today. This afternoon, we announced our Q4 2023 financial results and associated business plan business updates in a press release. This press release can be found within the Investors section of our website. With me today are Vince Angotti, our Chief Executive Officer and Doctor. Pam Palmer, Talferra's Founder and Chief Medical Officer.

Speaker 1

Before we begin, I want to remind listeners that during this call, we will likely make forward looking statements within the meaning of the federal securities laws. These forward looking statements involve risks and uncertainties regarding the operations and future results of Telferra. Please refer to our press release in addition to the company's periodic, current and annual reports filed with the Securities and Exchange Commission at www.sec.gov for a discussion of the risks associated with such forward looking statements. These documents can also be found on our website within the Investors section of telfera.com. I'll now hand the call over to Vince.

Speaker 2

Thank you, Raffi. Good afternoon to everyone, and welcome to the first call we're having as Talferra. Throughout 2023, we focused on our objective of repositioning the company around a new portfolio of assets with an immediate priority on NIAID and longer term strategy on the broader nafamostat pipeline and other pipeline assets. As these assets have the traits to drive our vision to support healthcare providers and optimizing patient outcomes in medically supervised settings. 2023 was a productive year in achieving this objective culminating in our ultimate rebranding to Taufera, signifying the completion of this repositioning.

Speaker 2

With this transition, we believe we've successfully capitalized Taufera to achieve our 2024 goal to advance Naya to a pre market application submission or PMA. Today, we'll number 1, highlight the activities completed in 2023 that have positioned Taufera for success over the next 12 to 18 months 2, identify the important upcoming milestones in 2024 and then 3, update you on the status of our NIAID registrational study. As for 2023, in April, we closed the transaction with Alor to divest DSUVIA to a partner with experience in manufacturing and commercializing controlled substances. This transaction allowed us to complete the reduction in our annual DSUVIA related operating by approximately $14,000,000 and refocus these resources on the development of NIAID. With this transaction, we earned royalties of 15% on commercial sales, 75% on sales to the Department of Defense and up to $116,500,000 in potential milestone payments.

Speaker 2

We're confident that Allora is the right partner and we expect they'll begin commercializing in 2024 after they complete all their work around restructuring and in sourcing the supply chain. In October, another pivotal success was achieved After several months of working on the NIAID study protocol and discussing modifications with the FDA, we received an approval of our IDE from the FDA. This allowed us to start preparations for the single registrational study that we expect to begin enrolling in the coming weeks. The clinical and regulatory teams have designed a 166 patient study as agreed to with the FDA that many of our KOLs believe should be quickly enrolled. Remember, nifanastat is an approved and longstanding product in Japan and South Korea for anticoagulation and other indications with a wealth of safety and efficacy information.

Speaker 2

Our nifamistat product candidate, NIAID, has received breakthrough designation from the FDA. We believe all of this bodes well for successful clinical trial this year. Doctor. Palmer will provide an overview of the study and its status later in the call. Another key achievement in 2023 was the December publication in the journal Renal Failure of our market research with 150 physicians in the U.

Speaker 2

S. Regarding the practices of anticoagulation of the extracorporeal CRRT circuit. Many of the authors of this study are in the process of becoming investigators in our clinical trial and have provided us with valuable information and better understanding how physicians are currently using anticoagulants during CRRT and the potential issues with current standards of care. We hosted 2 authors of this study and a KOL panel discussion in December, which provided interesting insights into the market and clinical practices at 2 leading academic institutions. We believe that nifanastat, if approved in the U.

Speaker 2

S, would be an important addition to the market for anticoagulation during CRRT, particularly given the disadvantages raised in this publication of the 2 anticoagulants currently used, those being heparin and citrate. If approved by the FDA, NIAID would be the only regional anticoagulant approved in the U. S. For the extracorporeal circuit. After achieving these 2023 objectives to reposition the company, we were prepared to proceed with corporate rebranding to ensure all stakeholders were aware of our new vision with a focus on NIAID in the near term.

Speaker 2

Accordingly, in January, we rebranded the company to Talferra. The new name was derived in part from Talisman, meaning a strong leader and reflects the new pharmaceutical era for the company. This signals the beginning of our newly transformed company We're excited about the momentum we have gained and the positive feedback we've received from the many investors we've met with over the last couple of months. Soon after the rebranding, importantly, we announced the completion of 2 financing events focused on ensuring we have sufficient capital to get to a potential approval of NIAID in the Q2 of next year. The first was a non dilutive royalty financing closed with ZOMO royalty, where we partially monetized our DSUVIA royalties Zoma in exchange for the royalties and milestones being paid by Alora.

Speaker 2

Once Zoma receives a specified amount of payments, we'll share equally in the Department of Defense royalties and the milestone payments. Separately, we closed an equity financing from 2 of our existing investors, Nantahala and Rosalind. The equity financing provides $18,000,000 in total funds structured over 2 closings. We received $6,000,000 at the first closing and another $10,000,000 of committed capital will be received at the 2nd closing upon the announcement of positive nephro trial data by September 30 this year and an additional $2,000,000 if TALFERA stock trades above $0.92 following that announcement. To be clear, this is committed capital once the milestones are met.

Speaker 2

In addition, should the milestone based warrants from the July 2023 financing be exercised, an additional $14,400,000 of capital would be injected into the company. Concurrent with the equity investment, we were delighted that Abhi Jain from Nantahala agreed to be on our Board of Directors, which adds further depth to our experienced Board. As you may have seen, we announced last week that the Board has decided to reduce the total number of directors to 7 from the 10 we previously had. This reduction is consistent with best governance practices of other companies our size. Accordingly, Howie Rosen, Rickofable and Pam Palmer voluntarily resigned from the Board.

Speaker 2

I'd like to expressly thank Howie Rosen and Rickofable for all their valuable contributions over the years on our Board. And of course look forward to continuing work with Doctor. Palmer as our Chief Medical Officer. Finally, before handing the call over to Doctor. Palmer, I'd like to remind everyone of all the upcoming milestones expected over the next 18 months.

Speaker 2

We anticipate our first patient in the NIAID study to be enrolled in the coming weeks. Once patients begin enrolling, we'll have a better overall sense of the timing, but based on feedback received from the various KOLs, we expect this study to enroll quickly. After 32 patients have been enrolled, there'll be a planned interim safety analysis. Top line data readout from the completed study would then be expected by the end of the third quarter with a PMA submission planned for the end of the year. Now with a 6 month FDA statutory timeline, this would put us on track for a potential PMA approval by the end of the Q2 of 2025.

Speaker 2

With that, I'll hand the call over to Doctor. Palmer, who will provide an update on the Nephros CRRT or NIAID clinical study. Pam?

Speaker 3

Thank you, Vince, and good afternoon to everyone. Today, I'll provide a brief update on the nephro study status as we've been eager to get the study started. Most of our clinical sites undergoing contracting with us are large academic institutions across the country, and we've experienced delays in administrative efforts to have our contracts and budgets in place to begin enrolling patients. We had expected to have our 1st patient enrolled already, but our CRO has confirmed that they are seeing similar administrative delays with institutions across many other studies as well. We do not expect to have any significant delays in enrolling patients once each site is set to start.

Speaker 3

As Vince mentioned, the feedback provided by KOLs is that they believe once they are set up to initiate the study, enrolling should be fairly rapid given the relatively short study period and broad inclusion criteria for the trial. Patients are considered completers after only 72 hours on CRRT and all primary and secondary endpoints are assessed during this period. This said, we expect the 1st patient to be enrolled in the coming weeks at our first site as we have recently completed the site initiation visit with an additional site initiation visit and other institutions scheduled for next week. As a reminder, our clinical study will include 166 patients with half receiving an infusion of NIAID into the CRRT circuit, while the other half will receive an infusion of saline as a placebo into the circuit. The primary endpoint will be the CRRT post filter activated clotting time over the first 24 hours, with a key secondary endpoint including the same measurement over 72 hours.

Speaker 3

Additional secondary endpoints evaluate filter lifespan, number of transfusions and dialysis efficacy. There are a number of reasons we are confident in the successful study outcome. 1st and foremost being the 3 decades of nifamostat's safe and effective clinical use in Japan and South Korea. Secondly, an independent meta analysis evaluating almost 3,000 patients published in 2022, analyzing the use of nifamistat as an anticoagulant for the extracorporeal circuit provides insightful data on mortality, bleeding risk and filter life, all of which were favorable for nafamostat as compared to conventional anticoagulant therapy or in the absence of an anticoagulant. Thirdly is the nephro CRRT straightforward study design in which we are comparing a proven powerful anticoagulant to saline and measuring an activated clotting time as a primary endpoint.

Speaker 3

The use of saline as a comparator in our study is ethical as we know from our recent published market research that nearly a third of CRRT patients received no anticoagulant. KOLs have informed us the main reason for not using an anticoagulant is that the current available options heparin and citrate carry risks that many patients cannot tolerate. Peperin is a systemic anticoagulant with a half life of up to 3 hours. Therefore, it circulates back into the patient from the circuit and should not be used in patients at risk of bleeding. By comparison, nifamistat has an ultra short half life of only 8 minutes, reducing the risk of systemically anticoagulating the patient.

Speaker 3

Various citrate formulations used either off label or under an EUA are complex to administer and have their own complications, including hypocalcemia, citrate toxicity and ventricular arrhythmias. While we do not have enough time here today to discuss all the disadvantages of citrate and heparin, suffice it to say, we believe that nifamistat, if approved, will be an important addition to the current anticoagulants being used. More information on the disadvantages of heparin and citrate as well as the risk of using no anticoagulant is detailed in the recently published market research study in the journal Renal Failure as well as by the KOL panel discussion that we hosted in December of last year. Both the publication and a webcast recording of the KOL panel can be found on our website. I will now turn the call back over to Vince.

Speaker 2

Thank you, Pam. We've previously discussed the peak sales potential of NIAID of $200,000,000 which is split fairly evenly between CRRT in the hospital setting and intermittent hemodialysis use in the outpatient setting. We will initially by concentrating on CRRT in the hospital as this is the focus of the Nephros CRRT clinical study. We're currently working on additional market research to inform potential updates to the market opportunity, pricing and market penetration potential of NIAID. Our pig sales potential assumes only a 19.5% market penetration in the hospital CRRT setting.

Speaker 2

However, feedback receiving from our KOLs indicates we may be underestimating our market penetration potential. We'll share any updates needed to our estimated peak sales following the completion of our additional market research. Now I'll hand the call over to Rafi to take you through the details of the financial results.

Speaker 1

Thank you, Vince. 2023 was clearly a year of transformation for Talferra, and we're excited about the prospects of our lead asset, NIAID, as well as the longer term potential

Speaker 4

within the

Speaker 1

Famostat portfolio. We are thankful for the support from our investors, including Nantahala and Rosalind, who participated in the January 2024 equity financing with the objective to ensure we have sufficient capital to reach a potential Q2 2025 PMA approval of NIAID. The company friendly structure of this equity financing, majority of which requires the investors to fund the company at the second closing should we achieve the pivotal trial milestone regardless of the stock price at the time, demonstrates the investors' conviction and belief in the company. Cash and cash equivalents were $9,400,000 at the end of the quarter or $23,400,000 on a pro form a basis if you include the $16,000,000 of initial proceeds received from the January financings. We continue to remain vigilant over our cash expenditures for the year.

Speaker 1

Our combined R and D and SG and A expenses excluding non cash stock compensation for the year were $15,800,000 slightly better than the guidance range of $16,000,000 to $20,000,000 we provided. For the quarter, the combined R and D and SG and A expenses, excluding $300,000 of non cash stock compensation, was $4,300,000 Our estimated full year 2024 combined R and D and SG and A expenses, excluding noncash stock related expense, are expected to range from $21,000,000 to $23,000,000 Revenues for the Q4 of $300,000 were generated from royalties on the sales of DSUVIA, principally from sales to the Department of Defense on which we earn a 75% royalty from Alora as stated earlier. We will continue to account for these royalties and milestones as revenues. However, there will be no cash flow impact going forward until Zoma receives their specified return and we begin sharing equally in the DoD royalties and the milestones. Given the historically variable nature of these revenues, we do not plan to provide any guidance on the expected timeframe on when these royalties and milestones will begin to generate cash flow to Talferra.

Speaker 1

I'll now turn the call back over to Vince.

Speaker 2

Thank you, Raffi. I'd now like to open the line for any questions you may have. Operator?

Operator

Thank you. Your first question comes from Ed Arce of H. C. Wainwright.

Speaker 4

Good afternoon, everyone. This is Thomas Hi, everyone. This is Thomas Yip asking a couple of questions for Ed. Thank you for taking my questions. So first, good to see that PMA submission is still on target by year end 2024.

Speaker 4

Just trying to tease out and that's really close to the end of Q1. Should we expect the 1st patient to be enrolled with by the end of the quarter? I believe you said within coming weeks and also I believe top line data is still on target in sometime in Q3 of this year?

Speaker 2

Yes. So I'll answer the first part of that. So again, reiterating what you mentioned, our target remains by the end of the year to have the PMA submission occurred. We've already completed an SIV or site initiation visit with one of the sites and other one scheduled for next week. And we'll monitor the enrollment from that point moving forward.

Speaker 2

Doctor. Palmer might be able to give you some additional color as it relates to discussions with the sites and the availability of patients moving forward and really what we just heard from the site we're visiting next week.

Speaker 3

Yes. So the sites are really excited to move forward. They're as frustrated, I think, by these administrative delays as we've been. They have even said to me, hey, Pam, I had 2 patients last week that would have qualified for the study. So they see these patients that they want to get in and we're just trying to get these SIVs, the site initiation visits done so they can quickly start enrolling.

Speaker 3

It is competitive enrollment, so there is no cap on any site. That means the first up and running will get to enroll more patients than the last. So we're really trying to move this forward and keep it on the timeline.

Speaker 2

Yes, I think in direct answer to your question by the end of Q1, that's certainly our goal, Thomas. And with the feedback, hopefully that's what we'll achieve here in short order.

Speaker 4

Got it. And then perhaps a follow-up on that for Doctor. Palmer. Can you discuss the nature of these administrative delays? You mentioned are these delays in all of the sites or just some of the sites that have been chosen?

Speaker 3

Yes. Well, no, it's actually kind of across the board. And what we've been hearing is these large academic centers, really had an exodus of administrative personnel in the past few years. A lot are working from home. They've been the numbers have been cut such that we are dealing with fewer folks in the contracting office and the budgeting office.

Speaker 3

And so when you put in your contracts and budgets, you're sort of queuing up for their attention. And so we are banging the drum and making phone calls and emailing and pestering as much as we can. But things are slowly starting to move, so we're excited. But no, they're almost all on the same timeline. So now we are starting to see these SIVs being scheduled and we're super excited because once we do meet with the team and we're doing these SIVs, the caliber of researchers that we're dealing with is very high.

Speaker 3

Their patient populations of qualify. They're seeing these patients every single day in their ICUs. And so, we just really feel like once we can get these sites kicked off, it'll be a nice rapid enrollment.

Speaker 2

Pam, can you comment quickly, we used the words or shortening of SIVs, site initiation visits. So we just started completing them, have more now scheduled. What is the site initiation?

Operator

Yes.

Speaker 3

So the site initiation visits were the last thing you do. You have to originally do confidentiality agreements. You have to do site feasibility questionnaires. You have to then negotiate a contract. You've got to negotiate a budget.

Speaker 3

All of that is what's taken a while. The very last thing you do before enrollment is a site initiation visit, where you're actually on-site looking at the pharmacy, looking at their data entry and things like that. So it really shows you there's a lot of paperwork and there's it just takes time to get through it. But once you get through it and get up and running, we're excited what we're hearing from the sites. I think they'll be able to roll this fairly quickly.

Speaker 2

And just to add a little additional color on the site initiation visits. We've already started completing some, have the additional ones really in the process of scheduling. They happen within a day. These aren't extended visits. It's less than a day visit at site by the CRO, just finishing up the final details.

Speaker 2

Hope that gives you some insight, Thomas, on that.

Speaker 4

Yes, definitely. That's helpful for the added details. And then, I believe, Scott, you mentioned on the call or maybe Vince that there will be an interim analysis from Nephro after DIR patients have been dosed. Will this be a blinded safety analysis? And what can we expect from after this analysis?

Speaker 3

Yes. It's a DSMB, a data safety management board. And what they do is they're a value yes, it is actually unblinded because they're selected to look at the data to make sure there's no safety signals. That's very typical for a new chemical entity that's not been approved yet in the U. S.

Speaker 3

Before. Although it's got 30 years of great history in Japan and South Korea, it's coming over here for the first time. So the first 32 patients, which will be 16 active, 16 placebo in general, are going to be evaluated by this unblinded committee and they give thumbs up or thumbs down to continue the study.

Speaker 4

Okay, got it. Understood. Thanks for clarity. And perhaps one question for Rafi. So cash runway up to Q2 next year, I believe so that includes the 16,000,000 dollars pro form a cash influx during the Q1 of 2024.

Speaker 4

Is that right?

Speaker 1

Yes. Just I need to correct my what I said in the prepared remarks, actually $14,000,000 on that first closing plus the royalty financing, not $16,000,000 So correct that there. So yes, that includes that plus the additional $12,000,000 that we're expecting once we announce the pivotal trial milestone or the top line data, which we're planning for in the Q3. It does not include I mean, obviously, as we mentioned in the prepared remarks, on top of that, should those July 2023 warrants be exercised, there's additional capital that comes into the company. Got

Speaker 4

it. That's on top. Okay. Thank you everyone for taking the questions and looking forward to the first patient's enrollment in the study.

Speaker 2

Yes. Well, operator, additional questions?

Speaker 1

Thanks, Thomas.

Operator

There are no further questions at this time. I would hand over the call to Vince Angotti for closing comments. Please go ahead.

Speaker 2

Thank you, operator. Before I give, final comments, there's clearly a high interest in the study and execution thereof. And Doctor. Palmer mentioned a component of the call to competitive enrollment. Doctor.

Speaker 2

Palmer, can you just give a quick elaboration on competitive enrollment?

Speaker 3

Yes. Basically, it's no site is capped. And so the first site that gets the SIV and gets the first patient in then has much longer period of time to enroll patients. And so, it's an incentive for all the sites to get up and running as quickly as they can. Otherwise, they will be limited in the number of patients they can enroll us there.

Speaker 2

I think a pretty important feature of the study design and contracts that we have with the sites. So with that as the final Q and A, I want to thank everyone for joining us today. As the new Talfera and also for your continued support. We certainly remain focused on driving long term shareholder value as a newly positioned company with a focus on executing this nephro study to make Nide available to the healthcare providers moving forward. We look forward to sharing future developments with you and thank you again for your continued interest and support in our company.

Speaker 2

Thank you.

Operator

Ladies and gentlemen, this concludes today's conference call. Thank you for your participation and you may now disconnect.

Remove Ads
Powered by Quartr
Earnings Conference Call
Talphera Q4 2023
00:00 / 00:00
Remove Ads